Table 2.
Surface under the cumulative ranking (SUCRA) value on various treatments with SCLC.
| Durvalumab | Atezolizumab | Nivolumab | Pembrolizumab | Ipilimumab | Durvalumab+Tremelimumab | Chemotherapy | Nivolumab+Ipilimumab | Serplulimab | Adebrelimab | |
|---|---|---|---|---|---|---|---|---|---|---|
| OS | 75.37% | 63.84% | 20.17% | 54.52% | 35.90% | 28.81% | 30.13% | 22.21% | 94.02% | 75.00% |
| PFS | 46.47% | 39.50% | 14.72% | 57.16% | 60.13% | 41.86% | 53.75% | 49.55% | 79.41% | 57.45% |
| DOR | 45.35% | 32.16% | 78.76% | - | 57.10% | - | 21.47% | 50.95% | 64.20% | - |
| SOR | 77.81% | 33.40% | 73.22% | 58.44% | 29.29% | - | 26.77% | 40.81% | 60.25% | - |
| Brain metastases | 63.05% | 38.35% | 62.45% | - | 12.52% | 51.60% | 42.08% | - | 79.97% | - |
| Without brain metastases | 55.66% | 67.58% | 39.56% | - | 22.40% | 48.27% | 20.43% | - | 77.33% | 68.77% |
| AE grade≥3 | 53.73% | 52.62% | 71.25% | - | 53.34% | 43.23% | 54.38% | 23.10% | 46.71% | 51.61% |
| Decreased appetite | 63.63% | 2.64% | 89.66% | 86.11% | 36.37% | 43.53% | 65.25% | 18.02% | - | 44.77% |
| Anemia | 48.45% | 66.45% | 99.08% | 37.48% | 37.85% | 43.75% | 37.23% | 42.02% | 47.99% | 39.69% |
| Diarrhea | 72.17% | 50.68% | 0.04% | 76.66% | 41.06% | 61.11% | 80.16% | 18.13% | - | - |
| Pruritus | 68.33% | 46.04% | 12.18% | 76.25% | 42.63% | 68.13% | 66.43% | 20.01% | - | - |
| Fatigue | 70.79% | 44.38% | 84.78% | 41.62% | 17.68% | 75.61% | 50.11% | 15.03% | - | - |
| Nausea | 75.40% | 73.99% | 62.41% | 59.88% | 59.70% | 53.87% | 52.66% | 49.33% | 6.53% | 6.24% |
Che, chemotherapy; Ate, Atezolizumab; Dur, Durvalumab; DurplusTre, Durvalumab + Tremelimumab; Ipi, Ipilimumab; Pem, Pembrolizumab; Ser, Serplulimab; Niv, Nivolumab; NivplusIpi, Nivolumab + Ipilimumab; Ade, Adebrelimab. PFS, progression-free survival; OS, overall survival; DOR, duration of response; SOR, stable of response; AE grade ≥ 3, adverse events of grade ≥ 3.